Thursday 15 October 2026
Export IVVD’s income statement to Excel — free account
Invivyd, Inc.
IVVD Healthcare Biotechnology
Invivyd, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $53.4 million, up 110.5% from fiscal 2024. In the quarter to June 2026, revenue grew 21.2%, EPS fell 16.7% and free cash flow fell 226.9%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
0.67
0.06
+9.84%
Follow IVVD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
3.74 | 7.96 | 7.21 | 4.78 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(22.69) | (27.52) | (9.65) | (6.48) | |
P/B ratio |
2.01 | 1.76 | 1.98 | 1.54 | |
Price to Tangible BV |
2.01 | 1.76 | 1.98 | 1.54 | |
EV/Sales |
2.04 | 3.72 | 3.91 | 2.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.27) | (3.42) | (2.77) | (1.09) | |
EV/FCF |
(1.27) | (3.41) | (2.75) | (1.08) | |
Quick Ratio |
2.13 | 7.04 | 6.18 | 5.52 | |
Current Ratio |
2.47 | 7.24 | 6.47 | 5.87 | |
Net Debt/EBITDA |
8.02 | 18.70 | 4.32 | 3.54 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.33 | 0.26 | 0.32 | 0.38 | |
Operating CF/Net income |
0.79 | 1.40 | 1.01 | 0.97 | |
Capex/Depreciation |
0.00 | 0.00 | (1.42) | (0.80) | |
Research and Development Expense of Revenue |
61.28% | 58.39% | 223.60% | 205.58% | |
Selling, General and Administrative Expense of Revenue |
114.39% | 107.94% | 182.75% | 206.27% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
23.41% | 14.90% | 19.62% | 20.27% | |
Graham Net Nets |
0.34 | 0.50 | 0.41 | 0.52 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(42.73%) | (12.96%) | (23.85%) | (37.93%) | |
Free Cash Flow Yield |
(42.97%) | (13.70%) | (19.74%) | (39.34%) | |
Revenue per Share |
0.08 | 0.10 | 0.04 | 0.04 | |
Operating CF per Share |
(0.05) | (0.09) | (0.13) | (0.13) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.09) | (0.14) | (0.14) | |
Cash per Share |
0.50 | 1.32 | 0.59 | 0.50 | |
Shareholders Equity per Share |
0.55 | 1.40 | 0.66 | 0.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.55 | 1.40 | 0.66 | 0.57 | |
Free Cash Flow |
(8.25) | (15.45) | (42.44) | (43.51) | |
Working Capital |
65.27 | 213.30 | 173.26 | 151.08 | |
Capital Expenditures |
0.00 | 0.00 | (0.73) | (0.51) | |
Net Current Asset Value |
63.68 | 212.12 | 166.22 | 144.31 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.04 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
9.00 | 12.41 | 10.10 | 9.96 | |
Average Payables |
17.91 | 12.10 | 5.38 | 13.77 | |
Average Assets |
150.54 | 203.20 | 172.74 | 154.01 | |
Average Common Equity |
88.11 | 154.54 | 128.60 | 111.93 |
Columns are period end dates